Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Mayo Clin Proc Innov Qual Outcomes
; 6(6): 536-551, 2022 Dec.
Article
en En
| MEDLINE
| ID: mdl-36277502
ACEi, angiotensin-converting enzyme inhibitor; ADA, American Diabetes Association; AR, androgen receptor; ARB, angiotensin II receptor blocker; ARTS, minerAlocorticoid Receptor Antagonist Tolerability Study; BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; DM, diabetes mellitus; DN, diabetic nephropathy; ESKD, end-stage kidney disease; FIDELIO-DKD, Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease; FIGARO-DKD, Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease; GLP-1 RA, glucagon-like peptide 1 receptor agonists; GR, glucocorticoid receptor; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; KDIGO, Kidney Disease Improving Global Outcomes; MR, mineralocorticoid receptor; MRA, mineralocorticoid receptor antagonist; PR, progesterone receptor; RAAS, reninangiotensinaldosterone system; RAS, reninangiotensin system; SGLT-2i, sodium-glucose cotransporter 2 inhibitor; T2DM, type 2 diabetes mellitus; UACR, urinary albumin-creatine ratio; eGFR, estimated glomerular filtration rate
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Risk_factors_studies
Idioma:
En
Revista:
Mayo Clin Proc Innov Qual Outcomes
Año:
2022
Tipo del documento:
Article
Pais de publicación:
Países Bajos